Manufacturing Establishments1
FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.
BioComp Pharma, Inc.
927726893
Products1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Urea 39% Cream
Product Details
Drug Labeling Information
Complete FDA-approved labeling information including indications, dosage, warnings, contraindications, and other essential prescribing details.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DESCRIPTION SECTION
This product is a keratolytic emollient which is a gentle, yet potent, tissue softener for skin.
Each gram contains 390 mg of urea in a vehicle consisting of: carbomer, cetyl alcohol, dimethyl isosorbide, glyceryl stearate, mineral oil, petrolatum, propylene glycol, sodium hydroxide, water, and xanthan gum.
Urea is a diamide of carbonic acid with the following chemical structure:
PHARMACOKINETICS SECTION
The mechanism of action of topically applied urea is not yet known.
CLINICAL PHARMACOLOGY SECTION
Urea gently dissolves the intercellular matrix which results in loosening the horny layer of skin and shedding scaly skin at regular intervals, thereby softening hyperkeratotic areas of the skin.
DOSAGE & ADMINISTRATION SECTION
Apply to affected area(s) twice per day or as directed by a physician. Rub in until completely absorbed.
CONTRAINDICATIONS SECTION
This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product.
WARNINGS SECTION
KEEP OUT OF REACH OF CHILDREN.
PRECAUTIONS SECTION
FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.
PREGNANCY SECTION
Category C.Animal reproduction studies have not been conducted with this product. It is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. This product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.
NURSING MOTHERS SECTION
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.
ADVERSE REACTIONS SECTION
Transient stinging, burning, itching or irritation may occur and normally disappear upon discontinuing the use of this product.
CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION
Long-term animal studies for carcinogenic potential have not been performed on this product to date. Studies on reproduction and fertility also have not been performed.
INFORMATION FOR PATIENTS SECTION
Patients should discontinue the use of this product if the condition becomes
worse or if a rash develops in the area being treated or
elsewhere. Avoid contact with eyes, lips and mucous membranes.
HOW SUPPLIED SECTION
8 oz. (227 g) bottles, NDC 44523-801-08
STORAGE AND HANDLING SECTION
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to
30°C (between 59°F to 86°F). Brief exposure to
temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic
temperature does not exceed 25°C (77°F); however, such exposure should be
minimized.
SPL UNCLASSIFIED SECTION
To reporta serious adverse event or obtain product information, call (866) 762-2365.
Manufactured for:
BIOCOMP PHARMA, INC.
San Antonio, TX 78230 1355
2100669 [00] R1021